Showing results (1771-1780 of 2,695) with videos related to

Sort By:
Pageof 270
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 5, 2015
Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathyShelley D Miyamoto, Anis Karimpour-Fard, Valencia Peterson, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapyXiaomei Peng, Haya Ascher-Svanum, Douglas E Faries, et al.
Clinical Nuclear Medicine|March 1, 1994
Late "rim sign"--a variant of an old signM E Spieth, J S Seder, J C Stauffer, et al.
Surgical Endoscopy|April 19, 2002
Bidirectional endoscopy in patients with fecal occult bloodJ P Velez, W H Schwesinger, J Stauffer, et al.
Journal of Medicinal Chemistry|June 4, 2025
Characterization of Hepatotropic Small Molecule Inhibitors of Hypoxia Inducible Factor Prolyl Hydroxylase in the Prevention of Oxygen-Induced RetinopathyChristie Campla, George Hoppe, Minzhong Yu, et al.
Atherosclerosis|May 7, 2013
Impaired fasting blood glucose is associated with increased endothelin-1 vasoconstrictor toneKyle J Diehl, Danielle L Templeton, Julie Ma, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 28, 2013
Combining efficacy and completion rates with no data imputation: a composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trialsJonathan Rabinowitz, Nomi Werbeloff, Ivo Caers, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|November 5, 2020
Assessment of macrovascular and microvascular function in aging malesMatthew C Babcock, Lyndsey E DuBose, Teresa L Witten, et al.
Elife|January 26, 2023
Recruitment of Polo-like kinase couples synapsis to meiotic progression via inactivation of CHK-2Liangyu Zhang, Weston T Stauffer, John S Wang, et al.
Advances in Therapy|August 12, 2019
Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisMarilyn K Glassberg, Steven D Nathan, Chin-Yu Lin, et al.
Pageof 270